Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: A cross-sectional study

Journal of Psychiatric Research

Volumn 63, Issue , 2015, Pages 58-64

  Fond, Guillaume ^a,b   Boyer, Laurent ^b,c   Gaman, Alexandru ^b   Laouamri, Hakim ^b   Attiba, Dodji ^b   Richard, Jean Romain ^a,b   Delavest, Marine ^b,d   Houenou, Josselin ^a,b,e   Le Corvoisier, Philippe ^f   Charron, Dominique ^g   Krishnamoorthy, Rajagopal ^h   Oliveira, José ^b,f   Tamouza, Ryad ^f   Yolken, Robert ^i,j   Dickerson, Faith ^j   Leboyer, Marion ^a,b   Hamdani, Nora ^a,b  

^a INSERM U955   (France)

^b Fondation FondaMental Fondation de coopération scientifique en santé mentale   (France)

^c HÔPITAL SAINTE MARGUERITE   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e NeuroSpin   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Sheppard Pratt   (United States)

more..

Author keywords

Antipsychotic drugs; Bipolar disorder; Mood stabilizer; Schizophrenia; Toxoplasma gondii; Valproate

Indexed keywords

LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; VALPROIC ACID; ANTIPARASITIC AGENT; PROTOZOON ANTIBODY; PSYCHOTROPIC AGENT;

ADULT; ANTIPROTOZOAL ACTIVITY; ARTICLE; BIPOLAR DISORDER; CROSS-SECTIONAL STUDY; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SUICIDE ATTEMPT; TOXOPLASMA GONDII; TOXOPLASMOSIS; URBAN AREA; YOUNG MANIA RATING SCALE; BLOOD; CLINICAL TRIAL; COMPLICATION; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; TOXOPLASMA; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES, PROTOZOAN; ANTIPARASITIC AGENTS; BIPOLAR DISORDER; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; TOXOPLASMA; TOXOPLASMOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84926418176     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.02.011     Document Type: Article

References (46)

1. Abi-Dargham A. Schizophrenia: overview and dopamine dysfunction. JClin Psychiatry 2014, 75:e31.
2. Addington D., Addington J., Maticka-Tyndale E. Rating depression in schizophrenia. A comparison of a self-report and an observer report scale. JNerv Ment Dis 1993, 181:561-565.
3. Alipour A., Shojaee S., Mohebali M., Tehranidoost M., Abdi Masoleh F., Keshavarz H. Toxoplasma infection in schizophrenia patients: a comparative study with control group. Iran J Parasitol 2011, 6:31-37.
4. Alvarado-Esquivel C., Sanchez-Anguiano L.F., Arnaud-Gil C.A., Lopez-Longoria J.C., Molina-Espinoza L.F., Estrada-Martinez S., et al. Toxoplasma gondii infection and suicide attempts: a case-control study in psychiatric outpatients. JNerv Ment Dis 2013, 201:948-952.
5. Arias I., Sorlozano A., Villegas E., de Dios Luna J., McKenney K., Cervilla J., et al. Infectious agents associated with schizophrenia: a meta-analysis. Schizophr Res 2012, 136:128-136.
6. Brown A.S., Patterson P.H. Maternal infection and schizophrenia: implications for prevention. Schizophr Bull 2011, 37:284-290.
7. Carruthers V.B. Host cell invasion by the opportunistic pathogen Toxoplasma gondii. Acta trop 2002, 81:111-122.
8. Collins P.Y., Patel V., Joestl S.S., March D., Insel T.R., Daar A.S., et al. Grand challenges in global mental health. Nature 2011, 475:27-30.
9. da Silva R.C., Langoni H. Toxoplasma gondii: host-parasite interaction and behavior manipulation. Parasitol Res 2009, 105:893-898.
10. Dailly E., Chenu F., Renard C.E., Bourin M. Dopamine, depression and antidepressants. Fundam Clin Pharmacol 2004, 18:601-607.
11. Emelia O., Amal R.N., Ruzanna Z.Z., Shahida H., Azzubair Z., Tan K.S., et al. Seroprevalence of anti-Toxoplasma gondii IgG antibody in patients with schizophrenia. Trop Biomed 2012, 29:151-159.
12. Etain B., Dumaine A., Mathieu F., Chevalier F., Henry C., Kahn J.P., et al. ASNAP25 promoter variant is associated with early-onset bipolar disorder and a high expression level in brain. Mol Psychiatry 2010, 15:748-755.
13. Fond G., Capdevielle D., Macgregor A., Attal J., Larue A., Brittner M., et al. Toxoplasma gondii: a potential role in the genesis of psychiatric disorders. Encephale 2013, 39:38-43.
14. Fond G., Hamdani N., Kapczinski F., Boukouaci W., Drancourt N., Dargel A., et al. Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand 2014, 129:163-179.
15. Fond G., Macgregor A., Tamouza R., Hamdani N., Meary A., Leboyer M., et al. Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. Eur Arch Psychiatry Clin Neurosci 2014, 264:179-183.
16. Geoffroy P.A., Etain B., Jamain S., Bellivier F., Leboyer M. Early onset bipolar disorder: validation from admixture analyses and biomarkers. Can J Psychiatry Revue Can de Psychiatrie 2013, 58:240-248.
17. Goodwin D.G., Strobl J.S., Lindsay D.S. Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures. JParasitol 2011, 97:148-151.
18. Hamdani N., Daban-Huard C., Lajnef M., Richard J.R., Delavest M., Godin O., et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. JAffect Disord 2013.
19. Hinze-Selch D., Daubener W., Eggert L., Erdag S., Stoltenberg R., Wilms S. Acontrolled prospective study of toxoplasma gondii infection in individuals with schizophrenia: beyond seroprevalence. Schizophr Bull 2007, 33:782-788.
20. Jamain S., Cichon S., Etain B., Muhleisen T.W., Georgi A., Zidane N., et al. Common and rare variant analysis in early-onset bipolar disorder vulnerability. PLoS One 2014, 9:e104326.
21. Jones-Brando L., Torrey E.F., Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophrenia Res 2003, 62:237-244.
22. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
23. Kay S.R., Opler L.A. The positive-negative dimension in schizophrenia: its validity and significance. Psychiatr Dev 1987, 5:79-103.
24. Kim K., Weiss L.M. Toxoplasma: the next 100years. Microbes Infect 2008, 10:978-984.
25. Mathieu F., Dizier M.H., Etain B., Jamain S., Rietschel M., Maier W., et al. European collaborative study of early-onset bipolar disorder: evidence for genetic heterogeneity on 2q14 according to age at onset. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:1425-1433.
26. Montgomery S.A., Asberg M. Anew depression scale designed to be sensitive to change. Br J Psychiatry J Ment Sci 1979, 134:382-389.
27. Nascimento F.S., de Rosalmeida Dantas C., Netto M.P., Mella L.F., Suzuki L.A., Banzato C.E., et al. Prevalence of antibodies to Toxoplasma gondii in patients with schizophrenia and mood disorders. Schizophr Res 2012.
28. Nogareda F., Le Strat Y., Villena I., De Valk H., Goulet V. Incidence and prevalence of Toxoplasma gondii infection in women in France, 1980-2020: model-based estimation. Epidemiol Infect 2014, 142:1661-1670.
29. Okusaga O., Langenberg P., Sleemi A., Vaswani D., Giegling I., Hartmann A.M., et al. Toxoplasma gondii antibody titers and history of suicide attempts in patients with schizophrenia. Schizophr Res 2011, 133:150-155.
30. Okusaga O., Postolache T.T. Toxoplasma gondii, the immune System, and suicidal behavior. The neurobiological basis of suicide 2012, Boca Raton, FL. Y. Dwivedi (Ed.).
31. Pearce B.D., Kruszon-Moran D., Jones J.L. The relationship between Toxoplasma gondii infection and mood disorders in the third National Health and Nutrition Survey. Biol Psychiatry 2012, 72:290-295.
32. Posner K., Brown G.K., Stanley B., Brent D.A., Yershova K.V., Oquendo M.A., et al. The columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011, 168:1266-1277.
33. Prandovszky E., Gaskell E., Martin H., Dubey J.P., Webster J.P., McConkey G.A. The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. PLoS One 2011, 6:e23866.
34. Selle V., Schalkwijk S., Vazquez G.H., Baldessarini R.J. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 2014, 47:43-52.
35. Shibre T., Alem A., Abdulahi A., Araya M., Beyero T., Medhin G., et al. Trimethoprim as adjuvant treatment in schizophrenia: a double-blind, randomized, placebo-controlled clinical trial. Schizophr Bull 2010, 36:846-851.
36. Sommer I.E., van Westrhenen R., Begemann M.J., de Witte L.D., Leucht S., Kahn R.S. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 2014, 40:181-191.
37. Tedla Y., Shibre T., Ali O., Tadele G., Woldeamanuel Y., Asrat D., et al. Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. Ethiop Med J 2011, 49:211-220.
38. Torrey E.F., Bartko J.J., Lun Z.R., Yolken R.H. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull 2007, 33:729-736.
39. Torrey E.F., Bartko J.J., Yolken R.H. Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr Bull 2012, 38:642-647.
40. Torrey E.F., Davis J.M. Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. Clin Schizophr Relat Psychoses 2012, 5:208-216.
41. Wang H.L., Wang G.H., Li Q.Y., Shu C., Jiang M.S., Guo Y. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr Scand 2006, 114:40-48.
42. Wang Z.T., Harmon S., O'Malley K.L., Sibley L.D. Reassessment of the role of aromatic amino acid hydroxylases and the effect of infection by Toxoplasma gondii on host dopamine levels. Infect Immun 2014.
43. Webster J.P., Lamberton P.H., Donnelly C.A., Torrey E.F. Parasites as causative agents of human affective disorders? the impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour. Proc Biol Sci 2006, 273:1023-1030.
44. Yolken R.H., Bachmann S., Ruslanova I., Lillehoj E., Ford G., Torrey E.F., et al. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin Infect Dis 2001, 32:842-844.
45. Yolken R.H., Dickerson F.B. Fuller torrey e. Toxoplasma and schizophrenia. Parasite Immunol 2009, 31:706-715.
46. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. Arating scale for mania: reliability, validity and sensitivity. Br J Psychiatry J Ment Sci 1978, 133:429-435.